Molecular marker could help spot pancreatic cancer early
CHAPEL HILL – Researchers at the University of North Carolina at Chapel Hill School of Medicine have identified a molecular marker of pancreatic cancer that may help spot the disease at its earliest stages, when it can be treated more successfully with surgery.
In a finding published April 26, 2010, in the online journal PLoS One, the researchers showed that a specific form of a protein called palladin is produced in large amounts in the "tumor nest," the cells that surround a pancreatic tumor.
By measuring the levels of this form of palladin in patient samples, doctors could have an improved way to screen for the deadly cancer, possibly catching it earlier than ever before, said senior study author Carol Otey, Ph.D., associate professor of cell and molecular physiology at UNC.
Otey is a member of the NC Translational and Clinical Sciences Institute (NC TRaCS), part of a collaborative effort of a national network of medical research institutions affiliated with the NIH Clinical and Translational Science Awards (CTSAs).
"The problem with pancreas cancer is it is almost never caught at an early stage," said Otey. "By the time a person develops suspicious symptoms, the disease has typically progressed too far. But if you can diagnose it early, it can be treated very effectively with surgery."
Showing posts with label lung cancer treatment. Show all posts
Showing posts with label lung cancer treatment. Show all posts
Wednesday, April 28, 2010
Tuesday, April 6, 2010
Pancreatic cancer - Wikipedia, the free encyclopedia
Pancreatic cancer - Wikipedia, the free encyclopedia
Pancreatic cancer is a malignant neoplasm of the pancreas. Each year in the United States, about 42,470 individuals are diagnosed with this condition and 35,240 die from the disease.[1] The prognosis is relatively poor but has improved; the three-year survival rate is now about thirty percent, but less than 5 percent of those diagnosed are still alive five years after diagnosis. Complete remission is still rather rare.[2]
About 95% of exocrine pancreatic cancers are adenocarcinomas (M8140/3). The remaining 5% include adenosquamous carcinomas, signet ring cell carcinomas, hepatoid carcinomas, colloid carcinomas, undifferentiated carcinomas, and undifferentiated carcinomas with osteoclast-like giant cells.[3] Exocrine pancreatic cancers are far more common than endocrine pancreatic cancers (also known as islet cell carcinomas), which make up about 1% of total cases.[4][5]
Posted using ShareThis
Pancreatic cancer is a malignant neoplasm of the pancreas. Each year in the United States, about 42,470 individuals are diagnosed with this condition and 35,240 die from the disease.[1] The prognosis is relatively poor but has improved; the three-year survival rate is now about thirty percent, but less than 5 percent of those diagnosed are still alive five years after diagnosis. Complete remission is still rather rare.[2]
About 95% of exocrine pancreatic cancers are adenocarcinomas (M8140/3). The remaining 5% include adenosquamous carcinomas, signet ring cell carcinomas, hepatoid carcinomas, colloid carcinomas, undifferentiated carcinomas, and undifferentiated carcinomas with osteoclast-like giant cells.[3] Exocrine pancreatic cancers are far more common than endocrine pancreatic cancers (also known as islet cell carcinomas), which make up about 1% of total cases.[4][5]
Posted using ShareThis
Subscribe to:
Posts (Atom)